AMPH
Price
$22.37
Change
-$0.14 (-0.62%)
Updated
Jul 25 closing price
Capitalization
2.11B
15 days until earnings call
RDY
Price
$14.67
Change
-$0.04 (-0.27%)
Updated
Jul 25 closing price
Capitalization
12.48B
89 days until earnings call
Interact to see
Advertisement

AMPH vs RDY

Header iconAMPH vs RDY Comparison
Open Charts AMPH vs RDYBanner chart's image
Amphastar Pharmaceuticals
Price$22.37
Change-$0.14 (-0.62%)
Volume$329.13K
Capitalization2.11B
Dr. Reddy's Laboratories
Price$14.67
Change-$0.04 (-0.27%)
Volume$1.11M
Capitalization12.48B
AMPH vs RDY Comparison Chart in %
Loading...
AMPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMPH vs. RDY commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a StrongBuy and RDY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (AMPH: $22.37 vs. RDY: $14.67)
Brand notoriety: AMPH and RDY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AMPH: 68% vs. RDY: 72%
Market capitalization -- AMPH: $2.11B vs. RDY: $12.48B
AMPH [@Pharmaceuticals: Other] is valued at $2.11B. RDY’s [@Pharmaceuticals: Other] market capitalization is $12.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).

  • AMPH’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 0 green, 5 red.
According to our system of comparison, RDY is a better buy in the long-term than AMPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).

  • AMPH’s TA Score: 5 bullish, 5 bearish.
  • RDY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AMPH and RDY are a good buy in the short-term.

Price Growth

AMPH (@Pharmaceuticals: Other) experienced а +8.49% price change this week, while RDY (@Pharmaceuticals: Other) price change was +1.96% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.51%. For the same industry, the average monthly price growth was +11.90%, and the average quarterly price growth was +74.65%.

Reported Earning Dates

AMPH is expected to report earnings on Aug 11, 2025.

RDY is expected to report earnings on Oct 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.51% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.5B) has a higher market cap than AMPH($2.11B). RDY has higher P/E ratio than AMPH: RDY (19.68) vs AMPH (16.69). RDY YTD gains are higher at: -6.500 vs. AMPH (-39.752). RDY has higher annual earnings (EBITDA): 84.9B vs. AMPH (240M). RDY has more cash in the bank: 72.4B vs. AMPH (257M). AMPH has less debt than RDY: AMPH (624M) vs RDY (19.9B). RDY has higher revenues than AMPH: RDY (271B) vs AMPH (644M).
AMPHRDYAMPH / RDY
Capitalization2.11B12.5B17%
EBITDA240M84.9B0%
Gain YTD-39.752-6.500612%
P/E Ratio16.6919.6885%
Revenue644M271B0%
Total Cash257M72.4B0%
Total Debt624M19.9B3%
FUNDAMENTALS RATINGS
AMPH vs RDY: Fundamental Ratings
AMPH
RDY
OUTLOOK RATING
1..100
456
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
9736
SMR RATING
1..100
4548
PRICE GROWTH RATING
1..100
8758
P/E GROWTH RATING
1..100
9265
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMPH's Valuation (63) in the Pharmaceuticals Other industry is in the same range as RDY (78) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (36) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMPH (97) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than AMPH’s over the last 12 months.

AMPH's SMR Rating (45) in the Pharmaceuticals Other industry is in the same range as RDY (48) in the Pharmaceuticals Generic industry. This means that AMPH’s stock grew similarly to RDY’s over the last 12 months.

RDY's Price Growth Rating (58) in the Pharmaceuticals Generic industry is in the same range as AMPH (87) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to AMPH’s over the last 12 months.

RDY's P/E Growth Rating (65) in the Pharmaceuticals Generic industry is in the same range as AMPH (92) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to AMPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHRDY
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
51%
Momentum
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
49%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 6 days ago
40%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
46%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 3 days ago
50%
Declines
ODDS (%)
Bearish Trend 17 days ago
70%
Bearish Trend 17 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CPNS26.540.02
+0.06%
Calamos Nasdaq-100 Str Alt Prt ETF-Sep
TIPX19.12N/A
N/A
SPDR® Blmbg 1-10 Year TIPS ETF
AGOX29.87N/A
N/A
Adaptive Alpha Opportunities ETF
JJGTF26.00N/A
N/A
Barclays Bank PLC
RIGS22.96-0.32
-1.39%
RiverFront Strategic Income ETF

AMPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMPH has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if AMPH jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMPH
1D Price
Change %
AMPH100%
-1.15%
AMRX - AMPH
40%
Loosely correlated
+0.75%
HROW - AMPH
32%
Poorly correlated
-2.81%
VTRS - AMPH
32%
Poorly correlated
+0.64%
PAHC - AMPH
31%
Poorly correlated
-0.88%
DVAX - AMPH
31%
Poorly correlated
+1.79%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.36%
COLL - RDY
31%
Poorly correlated
-1.03%
AMPH - RDY
28%
Poorly correlated
-1.15%
HROW - RDY
26%
Poorly correlated
-2.81%
OGI - RDY
26%
Poorly correlated
+1.32%
VTRS - RDY
26%
Poorly correlated
+0.64%
More